These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34856746)

  • 41. The endolysin of the Acinetobacter baumannii phage vB_AbaP_D2 shows broad antibacterial activity.
    Yuan Y; Li X; Wang L; Li G; Cong C; Li R; Cui H; Murtaza B; Xu Y
    Microb Biotechnol; 2021 Mar; 14(2):403-418. PubMed ID: 32519416
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.
    Tran TB; Cheah SE; Yu HH; Bergen PJ; Nation RL; Creek DJ; Purcell A; Forrest A; Doi Y; Song J; Velkov T; Li J
    J Antibiot (Tokyo); 2016 Jun; 69(6):415-21. PubMed ID: 26669752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibacterial and Synergistic Effects of Herbal Extracts in Combination with Amikacin and Imipenem Against Multidrug-Resistant Isolates of Acinetobacter.
    Fatemi N; Sharifmoghadam MR; Bahreini M; Khameneh B; Shadifar H
    Curr Microbiol; 2020 Sep; 77(9):1959-1967. PubMed ID: 32623484
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of Acinetobacter infections.
    Michalopoulos A; Falagas ME
    Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model.
    Song JY; Cheong HJ; Lee J; Sung AK; Kim WJ
    Int J Antimicrob Agents; 2009 Jan; 33(1):33-9. PubMed ID: 18835761
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Identification and bioevaluation of SRI-12742 as an antimicrobial agent against multidrug-resistant Acinetobacter baumannii.
    Shukla M; Soni I; Matsuyama K; Tran T; Tanga M; Gong L; Chopra S
    Int J Antimicrob Agents; 2018 Jul; 52(1):22-27. PubMed ID: 29501820
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Distribution of extended spectrum beta-lactamase resistance genes among nosocomial imipenem resistant A. Baumannii strains harboring BLAoxa-23 carbapenemases isolated from Ilam and Tehran.
    Taherikalani M; Sekawi Z; Azizi-Jalilian F; Keshavarz B; Soroush S; Akbari M; Emaneini M; Asadollahi P; Maleki MH; Mohammadi S; Pakzad I; Delpisheh A; Asadollahi K
    J Biol Regul Homeost Agents; 2013; 27(3):883-9. PubMed ID: 24152853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Molecular characterization of beta-lactamase-associated resistance in Acinetobacter baumannii strains isolated from clinical samples].
    Keskin H; Tekeli A; Dolapci İ; Öcal D
    Mikrobiyol Bul; 2014 Jul; 48(3):365-76. PubMed ID: 25052103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro activities of ceftazidime/avibactam alone or in combination with antibiotics against multidrug-resistant Acinetobacter baumannii isolates.
    Mataracı Kara E; Yılmaz M; Özbek Çelik B
    J Glob Antimicrob Resist; 2019 Jun; 17():137-141. PubMed ID: 30576787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
    Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
    Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Origanum vulgare essential oil: antibacterial activities and synergistic effect with polymyxin B against multidrug-resistant Acinetobacter baumannii.
    Amaral SC; Pruski BB; de Freitas SB; Allend SO; Ferreira MRA; Moreira C; Pereira DIB; Junior ASV; Hartwig DD
    Mol Biol Rep; 2020 Dec; 47(12):9615-9625. PubMed ID: 33190200
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combination inhibition activity of chlorhexidine and antibiotics on multidrug-resistant Acinetobacter baumannii in vitro.
    Lin F; Yu B; Wang Q; Yuan M; Ling B
    BMC Infect Dis; 2021 Mar; 21(1):266. PubMed ID: 33731026
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibacterial activity of carbapenem-based combinations againts multidrug-resistant Acinetobacter baumannii.
    Pongpech P; Amornnopparattanakul S; Panapakdee S; Fungwithaya S; Nannha P; Dhiraputra C; Leelarasamee A
    J Med Assoc Thai; 2010 Feb; 93(2):161-71. PubMed ID: 20301995
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam.
    Pachón-Ibáñez ME; Fernández-Cuenca F; Docobo-Pérez F; Pachón J; Pascual A
    J Antimicrob Chemother; 2006 Sep; 58(3):689-92. PubMed ID: 16870647
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancing the stability and therapeutic potential of the antimicrobial peptide Feleucin-K3 against Multidrug-Resistant a. Baumannii through rational utilization of a D-amino acid substitution strategy.
    An Y; Guo X; Yan T; Jia Y; Jiao R; Cai X; Deng B; Bao G; Li Y; Yang W; Wang R; Sun W; Xie J
    Biochem Pharmacol; 2024 Jul; 225():116269. PubMed ID: 38723723
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Mechanism of drug resistance of carbapenems-resistant Acinetobacter baumannii and the application of a combination of drugs in vitro].
    Zhao C; Xie W; Zhang W; Ye Z; Wu H
    Zhonghua Shao Shang Za Zhi; 2014 Apr; 30(2):166-70. PubMed ID: 24989663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vitro evaluation of antimicrobial combinations against imipenem-resistant Acinetobacter baumannii of different MICs.
    Zhu W; Wang Y; Cao W; Cao S; Zhang J
    J Infect Public Health; 2018; 11(6):856-860. PubMed ID: 30057349
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic activity of bile salts and their derivatives in combination with conventional antimicrobial agents against Acinetobacter baumannii.
    Aleksić Sabo V; Škorić D; Jovanović-Šanta S; Nikolić I; János C; Knežević P
    J Ethnopharmacol; 2021 Jan; 264():113266. PubMed ID: 32810621
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii.
    García-Quintanilla M; Carretero-Ledesma M; Moreno-Martínez P; Martín-Peña R; Pachón J; McConnell MJ
    Int J Antimicrob Agents; 2015 Dec; 46(6):696-702. PubMed ID: 26391380
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nosocomial imipenem-resistant Acinetobacter baumannii infections: epidemiology and risk factors.
    Dizbay M; Tunccan OG; Sezer BE; Hizel K
    Scand J Infect Dis; 2010 Oct; 42(10):741-6. PubMed ID: 20500117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.